drugset / Trial / NCT02034604

Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia

NCT02034604

Phase 4 Completed 194 enrolled Samsung Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate efficacy and safety of naftopidil in patient with neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia.

Timeline

Start
2013-12
Primary completion
2016-12
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Naftopidil Small molecule
Comparator Tamsulosin Other / unclassified

Indications

No indication recorded.